The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC).
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; Fulgent Genetics; G1 THerapeutics; GlaxoSmithKline; Isofol Medical; Jazz Pharmaceuticals; Merck Serono; Oncocyte; Roche
Consulting or Advisory Role - Bayer; BMS; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono
 
Anup Kasi
Honoraria - OncLive
Research Funding - Astellas Pharma (Inst); Bavarian Nordic (Inst); Cardiff Oncology (Inst); FibroGen (Inst); Geistlich Pharma (Inst); Halozyme (Inst); Novocure (Inst); Rafael Pharmaceuticals (Inst); TESARO (Inst)
Travel, Accommodations, Expenses - Halozyme; Rafael Pharmaceuticals
 
Lawrence Mendelsohn
No Relationships to Disclose
 
Timothy Lewis Cannon
Honoraria - AstraZeneca; Deciphera
Consulting or Advisory Role - Loxo; Navican
Other Relationship - Navican/ Intermountain Healthcare
 
Jason S. Starr
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen; Natera; Pfizer; Taiho Oncology; Tersera
Research Funding - Incyte (Inst); Leap Therapeutics; Macrogenics (Inst); Merus (Inst); Molecular Templates (Inst); Rafael Pharmaceuticals (Inst); Vedanta Biosciences (Inst)
 
Joleen M. Hubbard
Consulting or Advisory Role - Bayer (Inst); Merck; Taiho Oncology (Inst)
Research Funding - Bayer (Inst); Boston Biomedical (Inst); eFFECTOR Therapeutics (Inst); G1 Therapeutics (Inst); Hutchison MediPharma (Inst); Incyte (Inst); Merck (Inst); Pionyr (Inst); Seagen (Inst); Senhwa Biosciences (Inst); Taiho Pharmaceutical (Inst); Translational Research in Oncology (Inst); Treos Bio (Inst); Trovagene (Inst)
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Celularity; Daiichi Sankyo/UCB Japan; Eisai; Eisai; Exact Sciences; Foundation Medicine; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Treos Bio
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - AstraZeneca; Exelixis; Lilly; Merck (Inst); Pancreatic Cancer Action Network
 
Maya Ridinger
Employment - Cardiff Oncology
Stock and Other Ownership Interests - Cardiff Oncology
Travel, Accommodations, Expenses - Cardiff Oncology
 
Errin Samuelsz
Employment - Cardiff Oncology
Stock and Other Ownership Interests - Cardiff Oncology
 
Katherine L. Ruffner
Employment - ALX Oncology; Cardiff Oncology
Stock and Other Ownership Interests - ALX Oncology; Anthem; Biogen (I); Bristol-Myers Squibb; Cardinal Health; Change Healthcare; Clovis Oncology (I); CVS; Gilead Sciences; Merck; Merck Sharp & Dohme; Pfizer
 
Mark G. Erlander
Employment - Cardiff Oncology
Leadership - Cardiff Oncology
Stock and Other Ownership Interests - Cardiff Oncology
 
Daniel H. Ahn
Stock and Other Ownership Interests - Natera
Consulting or Advisory Role - Advanced Accelerator Applications; Eisai; Exelixis; Genentech/Roche
Research Funding - AstraZeneca; Bayer